Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

TA260 Migraine (chronic) - botulinum toxin type A: review proposal  information

TA260 Migraine (chronic) - botulinum toxin type A: appendix A - matrix of stakeholders (PDF 37 KB)

TA260 Migraine (chronic) - botulinum toxin type A: appendix B - GE proposal paper - June 2015 (PDF 178 KB)

TA260 Migraine (chronic) - botulinum toxin type A: press release information

Migraine (chronic) - botulinum toxin type A: equality impact assessment - guidance development (PDF 83 KB)

Migraine (chronic) - botulinum toxin type A: final appraisal determination information

Migraine (chronic) - botulinum toxin type A: final appraisal determination (PDF 351 KB)

Migraine (chronic) - botulinum toxin type A: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 426 KB)

Migraine (chronic) - botulinum toxin type A: consultee and commentator comments on the ACD

Migraine (chronic) - botulinum toxin type A: Allergan (PDF 3.31 MB)

Migraine (chronic) - botulinum toxin type A: Migraine Action (PDF 111 KB)

Migraine (chronic) - botulinum toxin type A: Migraine Trust (PDF 101 KB)

Migraine (chronic) - botulinum toxin type A: Association of British Neurologists (PDF 354 KB)

Migraine (chronic) - botulinum toxin type A: British Association for the Study of Headache (BASH) (PDF 56 KB)

Migraine (chronic) - botulinum toxin type A: British Pain Society (PDF 91 KB)

Migraine (chronic) - botulinum toxin type A: Migraine in Primary Care Advisors (PDF 71 KB)

Migraine (chronic) - botulinum toxin type A: Primary Care Neurology Service (PDF 135 KB)

Migraine (chronic) - botulinum toxin type A: Royal College of Nursing (PDF 60 KB)

Migraine (chronic) - botulinum toxin type A: Royal College of Physicians (PDF 102 KB)

Migraine (chronic) - botulinum toxin type A: Department of Health (PDF 5 KB)

Migraine (chronic) - botulinum toxin type A: Medicines and Healthcare Products Regulatory Agency (MHRA) (PDF 20 KB)

Migraine (chronic) - botulinum toxin type A: comments on the ACD received from the public through the NICE website (PDF 74 KB)

Migraine (chronic) - botulinum toxin type A: additional evidence submitted by Allergan

Migraine (chronic) - botulinum toxin type A: Australian report on botox for chronic migraine (PDF 952 KB)

Migraine (chronic) - botulinum toxin type A: appendix 4 (PDF 603 KB)

Migraine (chronic) - botulinum toxin type A: Evidence Review Group critique of additional evidence (PDF 210 KB)

Migraine (chronic) - botulinum toxin type A: Allergan response to request for additional clarification (PDF 322 KB)

Migraine (chronic) - botulinum toxin type A: Evidence Review Group critique of Allergan response to request for additional evidence (PDF 125 KB)

Migraine (chronic) - botulinum toxin type A: appraisal consultation

Migraine (chronic) - botulinum toxin type A: appraisal consultation document information

Migraine (chronic) - botulinum toxin type A: evaluation report

Migraine (chronic) - botulinum toxin type A: pre-meeting briefing (PDF 255 KB)

Migraine (chronic) - botulinum toxin type A: Evidence Review Group report (PDF 1.54 MB)

Migraine (chronic) - botulinum toxin type A: Evidence Review Group report - factual accuracy check (PDF 317 KB)

Migraine (chronic) - botulinum toxin type A: Allergan (PDF 3.31 MB)

Migraine (chronic) - botulinum toxin type A: clarification

Migraine (chronic) - botulinum toxin type A: NICE clarification letter (PDF 187 KB)

Migraine (chronic) - botulinum toxin type A: manufacturer response to the NICE clarification letter (PDF 825 KB)

Migraine (chronic) - botulinum toxin type A: patient group, professional group and NHS organisation submission statements

Migraine (chronic) - botulinum toxin type A: Migraine Action (PDF 127 KB)

Migraine (chronic) - botulinum toxin type A: Migraine Trust (PDF 95 KB)

Migraine (chronic) - botulinum toxin type A: Association of British Neurologists (PDF 76 KB)

Migraine (chronic) - botulinum toxin type A: British Association for the Study of Headache (PDF 60 KB)

Migraine (chronic) - botulinum toxin type A: British Pain Society (PDF 36 KB)

Migraine (chronic) - botulinum toxin type A: Migraine in Primary Care Advisor (PDF 61 KB)

Migraine (chronic) - botulinum toxin type A: Primary Care Neurology Service (PDF 61 KB)

Migraine (chronic) - botulinum toxin type A: Royal College of Anaesthetists (PDF 52 KB)

Migraine (chronic) - botulinum toxin type A: expert written personal statements

Migraine (chronic) - botulinum toxin type A: Ahmed (PDF 84 KB)

Migraine (chronic) - botulinum toxin type A: Ransome (PDF 104 KB)

Migraine (chronic) - botulinum toxin type A: Shanahan (PDF 96 KB)

Migraine (chronic) - botulinum toxin type A: utility correction

Migraine (chronic) - botulinum toxin type A: manufacturer utility correction document (PDF 75 KB)

Migraine (chronic) - botulinum toxin type A: Evidence Review Group review of utility correction (PDF 76 KB)

Migraine (chronic) - botulinum toxin type A: scoping EIA form (PDF 15 KB)

Migraine (chronic) - botulinum toxin type A: final scope (PDF 50 KB)

Migraine (chronic) - botulinum toxin type A: final matrix (PDF 32 KB)

Migraine (chronic) - botulinum toxin type A: response to consultee and commentator comments on the draft scope (PDF 177 KB)

Migraine (chronic) - botulinum toxin type A: response to consultee and commentator comments on the provisional matrix (PDF 43 KB)

Migraine (chronic) - botulinum toxin type A: appendix B - draft scope (pre-referral) March 2011 (PDF 54 KB)

Migraine (chronic) - botulinum toxin type A: appendix C - provisional matrix (pre-referral) March 2011 (PDF 32 KB)